Heather H. Cheng, MD, PhD, discusses the role of genetic testing in prostate cancer as it continues to evolve in this space. This year, the 2019 NCCN guidelines focused more on genetic testing in select patients with prostate cancer.
Videos
Bianca D. Santomasso, MD, PhD, discusses the challenges that exist for the treatment of patients with diffuse large B-cell lymphoma with CAR T-cell therapy.
Frontline TKI in Intermediate-Risk Renal Cell Carcinoma
Naval Daver, MD, explains the rationale for the phase II QUAZAR trial, which assessed the efficacy and safety of azacitidine in patients with acute myeloid leukemia.
First-Line PARPi Maintenance in Advanced Ovarian Cancer
Jeff P. <a>Sharman</a>, MD, discusses the safety profile of acalabrutinib that was demonstrated in <a href="https://www.targetedonc.com/conference/ash-2019/patients-with-cll-treated-on-the-elevatetn-trial-experience-improved-pfs-with-acalabrutinib"><strong>the phase III ELEVATE-TN trial</strong></a>. The trial evaluated acalabrutinib as a single agent or in combination with obinutuzumab versus obinutuzumab plus chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Andre Goy, MD, discusses the results from a small clinical trial, which was presented at the 2019 American Society of Hematology Annual Meeting that he found particularly significant for the treatment of patients with relapsed/refractory mantle cell lymphoma.
Laura Michaelis, MD, discusses the next steps for research in the treatment of myelofibrosis following the addition of fedratinib to the armamentarium of JAK inhibitors.
Adam M. Brufsky, MD, PhD, FACP, discusses the TBCRC049 trial, which looks at the safety and efficacy of the tucatinib/trastuzumab/capecitabine combination to treat leptomeningeal metastases in HER2-positive breast cancer.
Transplant-Eligible Newly Diagnosed Multiple Myeloma